News, Events and Publications

2025

SITC 2025: Enhancing affinity of the novel HER2-targeting IgE, EPS 232, elicits superior anti-tumour activity supporting use in cancers with ultra-low HER2 expression

View Poster

2025

AET 2025: Hybrid IgE-IgG1 antibodies (IgEG): a new antibody class that combines IgE and IgG functionality

View Poster

2025

PEGS 2025: Hybrid IgE-IgG1 antibodies (IgEG): a new antibody class that combines IgE and IgG functionality

View Poster

2025

An IgE antibody targeting HER2 identified by clonal selection restricts breast cancer growth via immune-stimulating activities, Journal of Experimental & Clinical Cancer Research

Available here

2025

Hybrid IgE-IgG1 antibodies (IgEG): a new antibody class that combines IgE and IgG functionality

Available here

2025

ASCO 2025: A Phase lb, Open-Label Trial of MOv18 IgE in Patients with Advanced Ovarian Cancer

View Poster

2025

EPS 226, a novel HER2 targeting IgE therapeutic, delivers immune dependent anti-tumor activity in preclinical models of breast cancer

View Poster

2023

Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial

Available here

2021

An interesting read, Nature highlights IgE cancer antibodies as a promising new technology to watch in 2021.
www.nature.com/articles/d41586-021-00191-z

Read more

2020

Phase 1 trial of MOv18 IgE, a first-in-class IgE antibody therapy for cancer

James Spicer, Bristi Basu, Ana Montes, Udai Banerji, Rebecca Kristeleit, Gareth J Veal, Christopher Corrigan, Stephen Till, George Nintos, Tim Brier, Ionut G Funingana, Joo Ern Ang, Kam Zaki, Annie Griffin1, Claire Barton, Paul Jones, Sarah Mellor, Susan Brook, Katie Stoddart, Christopher Selkirk,Simon Carroll, Heike Lentfer, Natalie Woodman, Amy Pope, Giulia Pellizzari, Mano Nakamura, KristinaM Ilieva, Atousa Khiabany, Chara Stavraka, Hannah Gould, Jitesh Chauhan, Heather J Bax, Sarah Pinder, Debra H Josephs & Sophia N Karagiannis

The slides presentation by Prof Spicer are

Available here

2017

Anti-Folate Receptor-α IgE but not IgG Recruits Macrophages to Attack Tumors via TNFα/MCP-1 Signaling.

Josephs DH, Bax HJ, Dodev T, Georgouli M, Nakamura M, Pellizzari G, Saul L, Karagiannis P, Cheung A, Herraiz C, Ilieva KM, Correa I, Fittall M, Crescioli S, Gazinska P, Woodman N, Mele S, Chiaruttini G, Gilbert AE, Koers A, Bracher M, Selkirk C, Lentfer H, Barton C, Lever E, Muirhead G, Tsoka S, Canevari S, Figini M, Montes A, Downes N, Dombrowicz D, Corrigan CJ, Beavil AJ, Nestle FO, Jones PS, Gould HJ, Sanz-Moreno V, Blower PJ, Spicer JF,Karagiannis SN.

Cancer Res. 2017 Mar 1;77(5):1127-1141. doi: 10.1158/0008-5472.CAN-16-1829. Epub 2017 Jan 17.
PMID:28096174

Read more

2015

Comparative reactivity of human IgE to cynomolgus monkey and human effector cells and effects on IgE effector cell potency.

Saul L, Josephs DH, Cutler K, Bradwell A, Karagiannis P, Selkirk C, Gould HJ, Jones P, Spicer JF, Karagiannis SN.
MAbs. 2014 Mar-Apr;6(2):509-22. doi: 10.4161/mabs.27828. Epub 2014 Jan 14.

PMID:24492303

Read more

2014

IgE immunotherapy: a novel concept with promise for the treatment of cancer.

Josephs DH, Spicer JF, Karagiannis P, Gould HJ, Karagiannis SN.
MAbs. 2014 Jan-Feb;6(1):54-72. doi: 10.4161/mabs.27029. Review.

PMID:24423620

Read more

2012

Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application.

Karagiannis SN, Josephs DH, Karagiannis P, Gilbert AE, Saul L, Rudman SM, Dodev T, Koers A, Blower PJ, Corrigan C, Beavil AJ, Spicer JF, Nestle FO, Gould HJ.
Cancer Immunol Immunother. 2012 Sep;61(9):1547-64. doi: 10.1007/s00262-011-1162-8. Epub 2011 Dec 3. Review.
PMID:22139135

Read more

2009

Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells.
Karagiannis P, Singer J, Hunt J, Gan SK, Rudman SM, Mechtcheriakova D, Knittelfelder R, Daniels TR, Hobson PS, Beavil AJ, Spicer J, Nestle FO, Penichet ML, Gould HJ, Jensen-Jarolim E, Karagiannis SN.

Cancer Immunol Immunother. 2009 Jun;58(6):915-30. doi: 10.1007/s00262-008-0607-1. Epub 2008 Oct 22.

PMID:18941743

Read more

2008

Role of IgE receptors in IgE antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cells.

Karagiannis SN, Bracher MG, Beavil RL, Beavil AJ, Hunt J, McCloskey N, Thompson RG, East N, Burke F, Sutton BJ, Dombrowicz D, Balkwill FR, Gould HJ.

Cancer Immunol Immunother. 2008 Feb;57(2):247-63. Epub 2007 Jul 27.

PMID:17657488

Read more

2007

IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells.

Karagiannis SN, Bracher MG, Hunt J, McCloskey N, Beavil RL, Beavil AJ, Fear DJ, Thompson RG, East N, Burke F, Moore RJ, Dombrowicz DD, Balkwill FR, Gould HJ.

J Immunol. 2007 Sep 1;179(5):2832-43.
PMID:17709497

Read more

2003

Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells.

Karagiannis SN, Wang Q, East N, Burke F, Riffard S, Bracher MG, Thompson RG, Durham SR, Schwartz LB, Balkwill FR, Gould HJ.
Eur J Immunol. 2003 Apr;33(4):1030-40.

PMID:12672069

Read more

1999

Comparison of IgE and IgG antibody-dependent cytotoxicity in vitro and in a SCID mouse xenograft model of ovarian carcinoma.

Gould HJ, Mackay GA, Karagiannis SN, O’Toole CM, Marsh PJ, Daniel BE, Coney LR, Zurawski VR Jr, Joseph M, Capron M, Gilbert M, Murphy GF, Korngold R.
Eur J Immunol. 1999 Nov;29(11):3527-37.

PMID: 10556807

Rea more